Details for Patent: 7,772,243

Which drugs does patent 7,772,243 protect, and when does it expire?

Patent 7,772,243 protects VIZIMPRO and is included in one NDA.

This patent has fifty-six patent family members in forty-six countries.

Summary for Patent: 7,772,243

Title:	4-phenylamino-quinazolin-6-yl-amides
Abstract:	This invention provides quinazoline compounds of the formula: wherein: R1 is halo; R2 is H or halo; R3 is a) C1-C3 alkyl, optionally substituted by halo; or b) —(CH2)n-morpholino, —(CH2)n-piperidine, —(CH2)n-piperazine, —(CH2)n—-piperazine-N(C1-C3 alkyl), —(CH2)n-pyrrolidine, or —(CH2)n-imidazole; n is 1 to 4; R4 is —(CH2)m-Het; Het is morpholine, piperidine, piperazine, piperazine-N(C1-C3 alkyl), imidazole, pyrrolidine, azepane, 3,4-dihydro-2H-pyridine, or 3,6-dihydro-2H-pyridine, each optionally substituted by alkyl, halo, OH, NH2, NH(C1-C3 alkyl) or N (C1-C3 alkyl)2; m is 1-3; and X is O, S or NH; or a pharmaceutically acceptable salt thereof, as well as processes and intermediate compounds for making them, useful pharmaceutical compositions and methods of using the compounds in the treatment of proliferative diseases.
Inventor(s):	Stephen Alan Fakhoury, Helen Tsenwhei Lee, Jessica Elizabeth Reed, Kevin Matthew Schlosser, Karen Elaine Sexton, Haile Tecle, Roy Thomas Winters
Assignee:	Warner Lambert Co LLC
Application Number:	US11/122,345
Patent Claim Types: see list of patent claims	Composition; Compound;

error: insufficient information

Drugs Protected by US Patent 7,772,243

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Pfizer	VIZIMPRO	dacomitinib	TABLET;ORAL	211288-001	Sep 27, 2018		RX	Yes	No			Y	Y
Pfizer	VIZIMPRO	dacomitinib	TABLET;ORAL	211288-002	Sep 27, 2018		RX	Yes	No			Y	Y
Pfizer	VIZIMPRO	dacomitinib	TABLET;ORAL	211288-003	Sep 27, 2018		RX	Yes	Yes			Y	Y

International Family Members for US Patent 7,772,243

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
European Patent Office	1746999		301004	Netherlands
European Patent Office	1746999		PA2019016	Lithuania
European Patent Office	1746999		122019000080	Germany
European Patent Office	1746999		2019C/540	Belgium
European Patent Office	1746999		LUC00127	Luxembourg
European Patent Office	1746999		CR 2019 00043	Denmark